1. Home
  2. HALO vs CFR Comparison

HALO vs CFR Comparison

Compare HALO & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HALO
  • CFR
  • Stock Information
  • Founded
  • HALO 1998
  • CFR 1868
  • Country
  • HALO United States
  • CFR United States
  • Employees
  • HALO N/A
  • CFR N/A
  • Industry
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • CFR Major Banks
  • Sector
  • HALO Health Care
  • CFR Finance
  • Exchange
  • HALO Nasdaq
  • CFR Nasdaq
  • Market Cap
  • HALO 7.4B
  • CFR 7.9B
  • IPO Year
  • HALO N/A
  • CFR N/A
  • Fundamental
  • Price
  • HALO $52.02
  • CFR $131.23
  • Analyst Decision
  • HALO Buy
  • CFR Hold
  • Analyst Count
  • HALO 9
  • CFR 15
  • Target Price
  • HALO $63.56
  • CFR $133.13
  • AVG Volume (30 Days)
  • HALO 3.1M
  • CFR 367.4K
  • Earning Date
  • HALO 05-06-2025
  • CFR 05-01-2025
  • Dividend Yield
  • HALO N/A
  • CFR 3.05%
  • EPS Growth
  • HALO 55.40
  • CFR 7.71
  • EPS
  • HALO 3.76
  • CFR 9.11
  • Revenue
  • HALO $1,084,306,000.00
  • CFR $2,038,108,000.00
  • Revenue This Year
  • HALO $24.79
  • CFR $11.62
  • Revenue Next Year
  • HALO $22.65
  • CFR $3.90
  • P/E Ratio
  • HALO $13.83
  • CFR $14.41
  • Revenue Growth
  • HALO 25.64
  • CFR 5.45
  • 52 Week Low
  • HALO $41.28
  • CFR $94.09
  • 52 Week High
  • HALO $70.51
  • CFR $147.64
  • Technical
  • Relative Strength Index (RSI)
  • HALO 39.78
  • CFR 68.66
  • Support Level
  • HALO $47.50
  • CFR $129.05
  • Resistance Level
  • HALO $69.94
  • CFR $131.82
  • Average True Range (ATR)
  • HALO 3.52
  • CFR 2.52
  • MACD
  • HALO -1.49
  • CFR 1.38
  • Stochastic Oscillator
  • HALO 19.64
  • CFR 96.63

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About CFR Cullen/Frost Bankers Inc.

Cullen/Frost is a regional US bank with around $50 billion in assets (as of 2024 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.

Share on Social Networks: